ASMARCAP and GAAPP request for support for asthma patients in Nigeria
20/12/2023
20/12/2023
The Global Allergy & Airways Patient Platform (GAAPP), the Asthma Relief Campaign Project (ASMARCAP), following the recent Global Respiratory Summit 2023 in Milan, wants to bring attention to the challenges faced by asthma patients in Nigeria since GlaxoSmithKline’s withdrawal from the country.
GSK Ventolin Inhalers have been the primary first aid medication for 95% of asthma patients in Nigeria. Since GSK´s departure from Nigeria, the cost of these inhalers has surged from 2000 Naira to 10,000 Naira and above, significantly burdening those affected. Asthma is a prevalent chronic condition affecting millions of individuals, including school-age children. Proper education about asthma empowers them to lead healthier lives and creates a safer, more informed school environment.
In light of these circumstances, we would like to request the following:
You can download the full letter in English:
if you have any inquiries, feel free to contact us at info@gaapp.org or call us at (+43) 6767534200